Antiepileptic drug monotherapy for epilepsy: A network meta-analysis of individual participant data

Cochrane Database of Systematic Reviews

Volumn 2017, Issue 6, 2017, Pages

  Nevitt, Sarah J ^a   Sudell, Maria ^a   Weston, Jennifer ^a   Tudur Smith, Catrin ^a   Marson, Anthony G ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; GABAPENTIN; LAMOTRIGINE; LEVETIRACETAM; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; TOPIRAMATE; VALPROIC ACID; ZONISAMIDE; 4 AMINOBUTYRIC ACID; AMINE; CYCLOHEXANECARBOXYLIC ACID DERIVATIVE; ETIRACETAM; FRUCTOSE; ISOXAZOLE DERIVATIVE; PIRACETAM; TRIAZINE DERIVATIVE;

ABSENCE; BEHAVIOR CHANGE; BEHAVIOR DISORDER; COGNITIVE DEFECT; DIZZINESS; DROWSINESS; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; EPILEPSY; FAINTNESS; FATIGUE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; META ANALYSIS; MIGRAINE; MONOTHERAPY; MOOD CHANGE; MULTICENTER STUDY (TOPIC); MYOCLONUS SEIZURE; PARESTHESIA; PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REMISSION; REVIEW; SEIZURE; SIDE EFFECT; SKIN DISEASE; SYSTEMATIC REVIEW; TONIC CLONIC SEIZURE; TREATMENT OUTCOME; ADULT; ANALOGS AND DERIVATIVES; CHILD; EPILEPSIES, PARTIAL; EPILEPSY, GENERALIZED; NETWORK META-ANALYSIS; FOCAL EPILEPSY; GENERALIZED EPILEPSY;

ADULT; AMINES; ANTICONVULSANTS; CARBAMAZEPINE; CHILD; CYCLOHEXANECARBOXYLIC ACIDS; EPILEPSIES, PARTIAL; EPILEPSY; EPILEPSY, GENERALIZED; FRUCTOSE; GAMMA-AMINOBUTYRIC ACID; HUMANS; ISOXAZOLES; NETWORK META-ANALYSIS; PHENOBARBITAL; PHENYTOIN; PIRACETAM; REMISSION INDUCTION; TRIAZINES; VALPROIC ACID;

EID: 85021317112     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD011412.pub2     Document Type: Review

References (251)

1. Aikia M, Kalviainen R, Sivenius J, Halonen T, Riekkinen PJ. Cognitive effects of oxcarbazepine and phenytoin monotherapy in newly diagnosed epilepsy: one year follow-up. Epilepsy Research 1992;11(3):199-203. 5829125
2. Banu SH, Jahan M, Koli UK, Ferdousi S, Khan NZ, Neville B. Side effects of phenobarbital and carbamazepine in childhood epilepsy: randomised controlled trial. BMJ 2007;334(7605):1207. 5829127
3. Baulac M, Brodie MJ, Patten A, Segieth J, Giorgi L. Efficacy and tolerability of zonisamide versus controlled-release carbamazepine for newly diagnosed partial epilepsy: a phase 3, randomised, double-blind, non-inferiority trial. Lancet Neurology 2012;11(7):579-88. 5829129
4. Bidabadi E. Comparison of the effects of phenobarbital versus carbamazepine as single drug therapy in partial seizure with secondary generalization in children. Epilepsia 2009;50(Suppl 10):167. Abstract no: p772 28th International Epilepsy Congress; Budapest 2009. 5829131
5. Bill PA, Vigonius U, Pohlmann H, Guerreiro CA, Kochen S, Saffer D, et al. A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in adults with previously untreated epilepsy. Epilepsy Research 1997;27(3):195-204. 5829133
6. Biton V, Levisohn P, Hoyler S, Vuong A, Hammer AE. Lamotrigine versus valproate monotherapy-associated weight change in adolescents with epilepsy: results from a post hoc analysis of a randomized, double-blind clinical trial. Journal of Child Neurology 2003;18(2):133-9. 5829135
7. Biton V, Mirza W, Montouris G, Vuong A, Hammer AE, Barrett PS. Weight change associated with valproate and lamotrigine monotherapy in patients with epilepsy. Neurology 2001;56(2):172-7. 5829136
8. Edwards KR, Sackellares JC, Vuong A, Hammer AE, Barrett PS. Lamotrigine monotherapy improves depressive symptoms in epilepsy: a double-blind comparison with valproate. Epilepsy & Behavior 2001;2(1):28-36. 5829137
9. Sackellares JC, Kwong WJ, Vuong A, Hammer AE, Barrett PS. Lamotrigine monotherapy improves health-related quality of life in epilepsy: a double-blind comparison with valproate. Epilepsy & Behavior 2002;3(4):376-82. 5829138
10. Brodie MJ, Richens A, Yuen AW. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Lancet 1995;345(8948):476-9. 5829140
11. Gillham R, Kane K, Bryant-Comstock L, Brodie MJ. A double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health-related quality of life as an outcome measure. Seizure 2000;9(6):375-9. 5829141
12. Severi S, Muscas GC, Bianchi A, Zolo P. Efficacy and safety of lamotrigine monotherapy in partial epilepsy. Bollettino - Lega Italiana Contro L'Epilessia 1994;86-7:149-51. 5829142
13. Brodie MJ, Richens A, Yuen AW. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Lancet 1995;345(8948):476-9. 5829144
14. Gillham R, Kane K, Bryant-Comstock L, Brodie MJ. A double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health-related quality of life as an outcome measure. Seizure 2000;9(6):375-9. 5829145
15. Severi S, Muscas GC, Bianchi A, Zolo P. Efficacy and safety of Lamotrigine monotherapy in partial epilepsy. Bollettino - Lega Italiana Contro L'Epilessia 1994;86-7:149-51. 5829146
16. Brodie MJ, Overstall PW, Giorgi L. Multicentre, double-blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy: The UK Lamotrigine Elderly Study Group. Epilepsy Research 1999;37(1):81-7. 5829148
17. Brodie MJ, Chadwick DW, Anhut H, Otte A, Messmer S-L, Maton S, et al. Gabapentin Study Group. Gabapentin versus lamotrigine monotherapy: a double-blind comparison in newly diagnosed epilepsy. Epilepsia 2002;43(9):993-1000. 5829150
18. Brodie MJ, Perucca E, Ryvlin P, Ben-Menachem E, Meencke HJ, Levetiracetam Monotherapy Study Group. Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. Neurology 2007;68(6):402-8. 5829152
19. Callaghan N, Kenny RA, O'Neill B, Crowley M, Goggin T. A prospective study between carbamazepine, phenytoin and sodium valproate as monotherapy in previously untreated and recently diagnosed patients with epilepsy. Journal of Neurology, Neurosurgery & Psychiatry 1985;48(7):639-44. 5829154
20. Goggin T, Casey C, Callaghan N. Serum levels of sodium valproate, phenytoin and carbamazepine and seizure control in epilepsy. Irish Medical Journal 1986;79(6):150-6. 5829155
21. Capone L, Carrieri L, Centrone G, Olivieri G, Ragno G, Roca M, et al. Randomised open trial of 35 subjects with epileptic seizures after stroke, treated with levetiracetam or carbamazepine CR. Bollettino - Lega Italiana Contro L'Epilessia 2008;138:203-6. 5829157
22. Castriota O, Guido M, Goffredo R, Di Claudio T, Specchio LM. Event-related potentials (ERPS) in the evaluation of the effect of levetiracetam and carbamazepine on cognitive functions in adult newly diagnosed epileptic patients. Preliminary results of an opened randomised trial. Bollettino - Lega Italiana Contro L'Epilessia 2008;138:235-7. 5829159
23. Chadwick DW, Anhut H, Greiner MJ, Alexander J, Murray GH, Garofalo EA, et al. A double-blind trial of gabapentin monotherapy for newly diagnosed partial seizures. International Gabapentin Monotherapy Study Group 945-77. Neurology 1998;51(5):1282-8. 5829161
24. Sasanelli F, Amodeo M, Colombo A, Molini GE. Gabapentin versus carbamazepine: monotherapy in newly-diagnosed patients with partial epilepsy: preliminary results. Bollettino - Lega Italiana Contro L'Epilessia 1996;95-96:185-6. 5829162
25. Chen YJ, Kang WM, So WC. Comparison of antiepileptic drugs on cognitive function in newly diagnosed epileptic children: a psychometric and neurophysiological study. Epilepsia 1996;37(1):81-6. 5829164
26. Cho YW, Kim DH, Motamedi GK. The effect of levetiracetam monotherapy on subjective sleep quality and objective sleep parameters in patients with epilepsy: compared with the effect of carbamazepine-CR monotherapy. Seizure 2011;20(4):336-9. 5829166
27. Christe W, Kramer G, Vigonius U, Pohlmann H, Steinhoff BJ, Brodie MJ, et al. A double-blind controlled clinical trial: oxcarbazepine versus sodium valproate in adults with newly diagnosed epilepsy. Epilepsy Research 1997;26(3):451-60. 5829168
28. Consoli D, Bosco D, Postorino P, Galati F, Plastino M, Perticoni GF, et al. EpIC Study. Levetiracetam versus carbamazepine in patients with late poststroke seizures: a multicenter prospective randomized open-label study (EpIC Project). Cerebrovascular Diseases 2012;34(4):282-9. 5829170
29. Cossu G, Monaco F, Piras MR, Grossi E. Short-term therapy with carbamazepine and phenobarbital: effects on cognitive functioning in temporal lobe epilepsy. Bollettino Lega Italiana contro l'Epilessia 1984;45/46:377-9. 5829172
30. Craig I, Tallis R. Impact of valproate and phenytoin on cognitive function in elderly patients: results of a single-blind randomized comparative study. Epilepsia 1994;35(2):381-90. 5829174
31. Tallis R, Easter D. Multicenter comparative trial of valproate and phenytoin. Epilepsia 1994;35(Suppl 7):62. 5829175
32. Czapinski P, Terczynski A. Open randomized comparative trial of sodium valproate and carbamazepine in adult onset epilepsy. Neurologia i Neurochirurgia Polska 1996;30(3):419-26. 5829178
33. Czapinski P, Terczynski A, Czapinska E. Randomised 36-month comparative study of valproic acid, phenytoin, phenobarbital and carbamazepine efficacy in patients with newly diagnosed epilepsy with partial complex seizures. Epilepsia 1997;38(Suppl(3)):42. 5829177
34. Dam M, Ekberg R, Loyning Y, Waltimo O, Jakobsen K. A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy. Epilepsy Research 1989;3(1):70-6. 5829180
35. de Silva M, MacArdle B, McGowan M, Hughes E, Stewart J, Neville BG, et al. Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet 1996;347(9003):709-13. 5829182
36. Dizdarer G, Kangin M, Sutcuoglu S, Ozmen Y, Yaprak I. A comparison of carbamazepine and oxcarbazepine in partial epilepsies. Epilepsia 2000;41(Suppl Florence):67-8. 5829184
37. Donati F, Gobbi G, Campistol J, Rapatz G, Daehler M, Sturm Y, et al. Oxcarbazepine Cognitive Study Group. The cognitive effects of oxcarbazepine versus carbamazepine or valproate in newly diagnosed children with partial seizures. Seizure 2007;16(8):670-9. 5829186
38. Eun S-H, Eun B-L, Lee JS, Hwang YS, Kim KJ, Lee Y-M, et al. Effects of lamotrigine on cognition and behavior compared to carbamazepine as monotherapy for children with partial epilepsy. Brain & Development 2012;34(10):818-23. 5829188
39. Feksi AT, Kaamugisha J, Sander JW, Gatiti S, Shorvon SD. Comprehensive primary health care antiepileptic drug treatment programme in rural and semi-urban Kenya. ICBERG (International Community-based Epilepsy Research Group). Lancet 1991;337(8738):406-9. 5829190
40. Berg I, Butler A, Ellis M, Foster J. Psychiatric aspects of epilepsy in childhood treated with carbamazepine, phenytoin or sodium valproate: a random trial. Developmental Medicine & Child Neurology 1993;35(2):149-57. 5829192
41. Forsythe I, Butler R, Berg I, McGuire R. Cognitive impairment in new cases of epilepsy randomly assigned to carbamazepine, phenytoin and sodium valproate. Developmental Medicine & Child Neurology 1991;33(6):524-34. 5829193
42. Fritz N, Elger C, Helmstaedter C. Effects of lamotrigine and oxcarbazepine on seizures, cognition, mood and health-related quality of life in patients with untreated epilepsy. Epilepsia 2006;47(Suppl 3):157. 5829195
43. Gilad R, Sadeh M, Rapoport A, Dabby R, Boaz M, Lampl Y. Monotherapy of lamotrigine versus carbamazepine in patients with poststroke seizure. Clinical Neuropharmacology 2007;30(4):189-95. 5829197
44. Guerreiro MM, Vigonius U, Pohlmann H, de Manreza ML, Fejerman N, Antoniuk SA, et al. A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in children and adolescents with epilepsy. Epilepsy Research 1997;27(3):205-13. 5829199
45. Heller AJ, Chesterman P, Elwes RD, Crawford P, Chadwick D, Johnson AL, et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. Journal of Neurology, Neurosurgery & Psychiatry 1995;58(1):44-50. 5829201
46. Jung DE, Yu R, Yoon JR, Eun BL, Kwon SH, Lee YJ, et al. Neuropsychological effects of levetiracetam and carbamazepine in children with focal epilepsy. Neurology 2015;84(23):2312-9. 5829203
47. Kalviainen R, Tigaran S, Keranen T, Peltola J, Aikia M. Open, multicenter, randomised comparison of cognitive effects of lamotrigine and slow-release carbamazepine monotherapy in newly diagnosed patients with epilepsy. Epilepsia 2002;43(Suppl 8):47. 5829205
48. Kopp UA, Gaus V, Wandschneider B, Schmitz B. Cognitive side effects of levetiracetam in monotherapy: comparison with carbamazepine and valproate. Epilepsia 2007;48(Suppl 3):39-40, Abstract No: P178. 5829207
49. Korean Lamotrigine Study Group. An open, randomized, multicenter comparative clinical trial of lamotrigine and carbamazepine as initial monotherapy in previously untreated epilepsies. Journal of Korean Epilepsy Society 2008;12(1):27-34. 5829209
50. Kwan P, Yip FP, Hui ACF, Leung H, Ng PW, Hui KF, et al. Effects of valproate or lamotrigine monotherapy on the reproductive endocrine and insulin-related metabolic profile in Chinese adults with epilepsy: a prospective randomized study. Epilepsy & Behavior 2009;14(4):610-6. 5829211
51. Ju KM, Lee SA, Lee HW, Heo K, Shin DJ, Song HK, et al. Effect of seizures on cognition, behavior, and quality of life during carbamazepine or lamotrigine monotherapy in patients with newly diagnosed partial epilepsy. Epilepsy currents / American Epilepsy Society 2011;11(Suppl 1):399, Abstract no: 3.090. 5829213
52. Lee S-A, Lee H-W, Heo K, Shin D-J, Song H-K, Kim O-J, et al. Cognitive and behavioral effects of lamotrigine and carbamazepine monotherapy in patients with newly diagnosed or untreated partial epilepsy. Seizure 2011;20(1):49-54. 5829214
53. Lee SA, Kim MJ, Lee HW, Heo K, Shin DJ, Song HK, et al. The effect of recurrent seizures on cognitive, behavioral, and quality-of-life outcomes after 12 months of monotherapy in adults with newly diagnosed or previously untreated partial epilepsy. Epilepsy & Behavior 2015;53:202-8. 5829215
54. Lukic SR, Spasic MJ, Lukic NR. Comparison of valproate and lamotrigine for the treatment of newly diagnosed epilepsy: interim report. Epilepsia 2005;46(Suppl 6):278. 5829217
55. Mattson RH, Cramer JA, Collins JF, Smith DB, Delgado-Escueta AV, Browne TR, et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures. New England Journal of Medicine 1985;313(3):145-51. 5829219
56. Mattson RH, Cramer JA, Collins JF. A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. The Department of Veterans Affairs Epilepsy Cooperative Study No. 264 Group. New England Journal of Medicine 1992;327(11):765-71. 5829221
57. Mitchell WG, Chavez JM. Carbamazepine versus phenobarbital for partial onset seizures in children. Epilepsia 1987;28(1):56-60. 5829223
58. Miura H. Aspects of antiepileptic drug therapy in children. No to Hattatsu [Brain & Development] 1990;22(2):154-9. 5829225
59. Motamedi M, Ghini MR, Etemadi P, Ramim T. Levetiracetam and lamotrigine in old aged onset of epilepsy: a randomized double-blind clinical trial. Tehran University Medical Journal 2013;71(9):568-76. 5829227
60. NCT01498822. Levetiracetam versus oxcarbazepine as monotherapy to evaluate efficacy and safety in subjects with partial epilepsy. ClinicalTrials.gov (accessed 23 August 2016). 5829229
61. NCT01954121. Open-label, randomized, active-controlled study of LEV used as monotherapy in patients with partial-onset seizures. ClinicalTrials.gov (accessed 23 August 2016). 5829231
62. Nieto-Barrera M, Brozmanova M, Capovilla G, Christe W, Pedersen B, Kane K, et al. Lamictal vs. Carbamazepine Study Group. A comparison of monotherapy with lamotrigine or carbamazepine in patients with newly diagnosed partial epilepsy. Epilepsy Research 2001;46(2):145-55. 5829233
63. Ogunrin O, Adamolekun B, Ogunniyi A. Cognitive effects of anti-epileptic drugs in Nigerians with epilepsy. African Journal of Neurological Sciences 2005;24(1):18-24. 5829235
64. Pal DK, Das T, Chaudhury G, Johnson AL, Neville BG. Randomised controlled trial to assess acceptability of phenobarbital for childhood epilepsy in rural India. Lancet 1998;351(9095):19-23. 5829237
65. Placencia M, Sander JW, Shorvon SD, Roman M, Alarcon F, Bimos C, et al. Antiepileptic drug treatment in a community health care setting in northern Ecuador: a prospective 12-month assessment. Epilepsy Research 1993;14(3):237-44. 5829239
66. Privitera MD, Brodie MJ, Mattson RH, Chadwick DW, Neto W, Wang S, EPMN study group. Topiramate, carbamazepine and valproate monotherapy: double-blind comparison in newly diagnosed epilepsy. Acta Neurologica Scandinavica 2003;107(3):165-75. 5829241
67. Wheless JW, Neto W, Wang S, EPMN study group. Topiramate, carbamazepine, and valproate monotherapy: double-blind comparison in children with newly diagnosed epilepsy. Journal of Child Neurology 2004;19(2):135-41. 5829242
68. Pulliainen V, Jokelainen M. Effects of phenytoin and carbamazepine on cognitive functions in newly diagnosed epileptic patients. Acta Neurologica Scandinavica 1994;89(2):81-6. 5829244
69. Ramsay RE, Wilder BJ, Berger JR, Bruni J. A double-blind study comparing carbamazepine with phenytoin as initial seizure therapy in adults. Neurology 1983;33(7):904-10. 5829246
70. Ramsay RE, Wilder BJ, Murphy JV, Holmes GL, Uthman B, Slater J, et al. Efficacy and safety of valproic acid versus phenytoin as sole therapy for newly diagnosed primary generalized tonic-clonic seizures. Journal of Epilepsy 1992;5(1):55-60. 5829248
71. Wilder BJ, Ramsay RE, Murphy JV, Karas BJ, Marquardt K, Hammond EJ. Comparison of valproic acid and phenytoin in newly diagnosed tonic-clonic seizures. Neurology 1983;33(11):1474-6. 5829249
72. Ramsay T, Bainbridge J, Fredericks T, Slater J, Nemire R, Ramsay RE. Results of a randomized double-blind comparison of levetiracetam and carbamazepine in new onset seizures in a geriatric population. Epilepsia 2007;48(Suppl 6):36-7. 5829251
73. Ramsay E, Faught E, Krumholz A, Naritoku D, Privitera M, Schwarzman L, et al. Capss Study Group. Efficacy, tolerability, and safety of rapid initiation of topiramate versus phenytoin in patients with new-onset epilepsy: a randomized double-blind clinical trial. Epilepsia 2010;51(10):1970-7. 5829253
74. Rastogi P, Mehrotra TN, Agarwala RK, Singh VS. Comparison of sodium valproate and phenytoin as single drug treatment in generalised and partial epilepsy. Journal of the Association of Physicians of India 1991;39(8):606-8. 5829255
75. Ravi Sudhir RV, Sawhney IMS, Prabhakar S, Pershad D, Nain CK. Comparative cognitive effects of phenytoin and carbamazepine in adult epileptics. Neurology India 1995;43(4):186-92. 5829257
76. Resendiz-Aparicio JC, Rodriguez-Rodriguez E, Contreras-Bernal J, Ceja-Moreno H, Barragan-Perez E, Garza-Morales S, et al. A randomised open trial comparing monotherapy with topiramate versus carbamazepine in the treatment of paediatric patients with recently diagnosed epilepsy. Revista de Neurologia 2004;39(3):201-4. 5829259
77. Reunanen M, Dam M, Yuen AW. A randomised open multicentre comparative trial of lamotrigine and carbamazepine as monotherapy in patients with newly diagnosed or recurrent epilepsy. Epilepsy Research 1996;23(2):149-55. 5829261
78. Richens A, Davidson DL, Cartlidge NE, Easter DJ. A multicentre comparative trial of sodium valproate and carbamazepine in adult onset epilepsy. Adult EPITEG Collaborative Group. Journal of Neurology, Neurosurgery & Psychiatry 1994;57(6):682-7. 5829263
79. Rowan AJ, Ramsay RE, Collins JF, Pryor F, Boardman KD, Uthman BM, et al. Cooperative Study 428 Group. New onset geriatric epilepsy: a randomized study of gabapentin, lamotrigine, and carbamazepine. Neurology 2005;64(11):1868-73. 5829265
80. Saetre E, Perucca E, Isojarvi J, Gjerstad L, Group LAMS. An international multicenter randomized double-blind controlled trial of lamotrigine and sustained-release carbamazepine in the treatment of newly diagnosed epilepsy in the elderly. Epilepsia 2007;48(7):1292-302. 5829267
81. Marson AG, Al-Kharusi AM, Alwaidh M, Appleton R, Baker GA, Chadwick DW, et al. SANAD Study Group. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet 2007;369(9566):1000-15. 5829269
82. Marson AG, Al-Kharusi AM, Alwaidh M, Appleton R, Baker GA, Chadwick DW, et al. SANAD Study Group. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet 2007;369(9566):1016-26. 5829271
83. Shakir RA, Johnson RH, Lambie DG, Melville ID, Nanda RN. Comparison of sodium valproate and phenytoin as single drug treatment in epilepsy. Epilepsia 1981;22(1):27-33. 5829273
84. So EL, Lai CW, Pellock J, Mashman J, Brugger A. Safety and efficacy of valproate and carbamazepine in the treatment of complex partial seizures. Journal of Epilepsy 1992;5(3):149-52. 5829275
85. Steiner TJ, Dellaportas CI, Findley LJ, Gross M, Gibberd FB, Perkin GD, et al. Lamotrigine monotherapy in newly diagnosed untreated epilepsy: a double-blind comparison with phenytoin. Epilepsia 1999;40(5):601-7. 5829277
86. Steinhoff BJ, Ueberall MA, Siemes H, Kurlemann G, Schmitz B, Bergmann L, LAM Safe Study Group. The LAM-SAFE Study: lamotrigine versus carbamazepine or valproic acid in newly diagnosed focal and generalised epilepsies in adolescents and adults. Seizure 2005;14(8):597-605. 5829279
87. Stephen LJ, Sills GJ, Leach JP, Butler E, Parker P, Hitiris N, et al. Sodium valproate versus lamotrigine: a randomised comparison of efficacy, tolerability and effects on circulating androgenic hormones in newly diagnosed epilepsy. Epilepsy Research 2007;75(2-3):122-9. 5829281
88. Suresh SH, Chakraborty A, Virupakshaiah A, Kumar N. Efficacy and safety of levetiracetam and carbamazepine as monotherapy in partial seizures. Epilepsy research and treatment 2015;2015:Article ID 415082. 5829283
89. Thilothammal N, Banu K, Ratnam RS. Comparison of phenobarbitone, phenytoin with sodium valproate: randomized, double-blind study. Indian Pediatrics 1996;33(7):549-55. 5829285
90. Trinka E, Marson AG, Van Paesschen W, Kälviäinen R, Marovac J, Duncan B, et al. KOMET: an unblinded, randomised, two parallel-group, stratified trial comparing the effectiveness of levetiracetam with controlled-release carbamazepine and extended-release sodium valproate as monotherapy in patients with newly diagnosed epilepsy. Journal of Neurology, Neurosurgery and Psychiatry 2013;84(10):1138-47. 5829287
91. Turnbull DM, Howel D, Rawlins MD, Chadwick DW. Which drug for the adult epileptic patient: phenytoin or valproate?. British Medical Journal 1985;290(6471):815-9. 5829289
92. Turnbull DM, Rawlins MD, Weightman D, Chadwick DW. A comparison of phenytoin and valproate in previously untreated adult epileptic patients. Journal of Neurology, Neurosurgery & Psychiatry 1982;45(1):55-9. 5829290
93. Easter D, O'Bryan-Tear CG, Verity C. Weight gain with valproate or carbamazepine - a reappraisal. Seizure 1997;6(2):121-5. 5829292
94. Verity CM, Hosking G, Easter DJ. A multicentre comparative trial of sodium valproate and carbamazepine in paediatric epilepsy. The Paediatric EPITEG Collaborative Group. Developmental Medicine & Child Neurology 1995;37(2):97-108. 5829293
95. Werhahn KJ, Trinka E, Dobesberger J, Ruckes C, Krämer G. Levetiracetam is superior to carbamazepine-SR in newly diagnosed epilepsy in the elderly: results of the step-one trial. Epilepsia 2012;53 Suppl. 5:49, Abstract no: p164. 5829295
96. Werhahn KJ, Trinka E, Dobesberger J, Unterberger I, Baum P, Deckert-Schmitz M, et al. A randomized, double-blind comparison of antiepileptic drug treatment in the elderly with new-onset focal epilepsy. Epilepsia 2015;56(3):450-9. 5829296
97. Wild I, Noack-Rink M, Ramirez F, Tofighy A, Werhahn K. Comparative effectiveness of the antiepileptic drugs (AEDs) levetiracetam, valproate and carbamazepine among patients aged 60 years and over with newly diagnosed epilepsy. Journal of Neurology 2014;261(Suppl 1):S159-S60, Abstract no: EP2238. 5829297
98. Albani F, Baruzzi A, Primo Study Group. Oxcarbazepine long-term treatment retention in patients switched over from carbamazepine. Neurological Sciences 2006;27(3):173-5. 5829299
99. Alsaadi TM, Thieman C, Zusman EE. Levetiracetam monotherapy for adults with localization-related epilepsy. Epilepsy and Behavior 2002;3(5):471-4. 5829301
100. Alsaadi TM, Shatzel A, Marquez AV, Jorgensen J, Farias S. Clinical experience of levetiracetam monotherapy for adults with epilepsy: 1-year follow-up study. Seizure 2005;14(2):139-42. 5829303
101. Baxter L, Cheesbrough A. An open randomised comparison of Lamictal (lamotrigine) with physicians preferred choice of either valproate or carbamazepine as monotherapy in patients over 12 years of age with newly diagnosed epilepsy. Clinical summary report 1998. 5829305
102. Ben-Menachem E. Preliminary efficacy of levetiracetam in monotherapy. Epileptic Disorders 2003;5(Suppl 1):S51-5. 5829307
103. Beydoun A, Fischer J, Labar DR, Harden C, Cantrell D, Uthman BM, et al. Gabapentin monotherapy: II. A 26-week, double-blind, dose-controlled, multicenter study of conversion from polytherapy in outpatients with refractory complex partial or secondarily generalized seizures. The US Gabapentin Study Group 82/83. Neurology 1997;49(3):746-52. 5829309
104. Beydoun A, Fakhoury T, Nasreddine W, Abou-Khalil B. Conversion to high dose gabapentin monotherapy in patients with medically refractory partial epilepsy. Epilepsia 1998;39(2):188-93. 5829311
105. Beydoun A, Sachdeo RC, Rosenfeld WE, Krauss GL, Sessler N, Mesenbrink P, et al. Oxcarbazepine monotherapy for partial-onset seizures: a multicenter, double-blind, clinical trial. Neurology 2000;54(12):2245-51. 5829313
106. Bittencourt PR, Antoniuk SA, Bigarella MM, da Costa JC, Doro MP, Ferreira AS, et al. Carbamazepine and phenytoin in epilepsies refractory to barbiturates: efficacy, toxicity and mental function. Epilepsy Research 1993;16(2):147-55. 5829315
107. Bawden HN, Camfield CS, Camfield PR, Cunningham C, Darwish H, Dooley JM, et al. The cognitive and behavioural effects of clobazam and standard monotherapy are comparable. Canadian Study Group for Childhood Epilepsy. Epilepsy Research 1999;33(2-3):133-43. 5829317
108. Cereghino JJ, Brock JT, Van Meter JC, Penry JK, Smith LD, White BG. Carbamazepine for epilepsy. A controlled prospective evaluation. Neurology 1974;24(5):401-10. 5829319
109. Chung S, Ceja H, Gawlowicz J, Avakyan G, McShea C, Schiemann J, et al. Levetiracetam extended release conversion to monotherapy for the treatment of patients with partial-onset seizures: a double-blind, randomised, multicentre, historical control study. Epilepsy Research 2012;101(1-2):92-102. 5829321
110. DeToledo JC, Ramsay RE, Lowe MR, Greiner M, Garofalo EA. Increased seizures after discontinuing carbamazepine: results from the gabapentin monotherapy trial. Therapeutic Drug Monitoring 2000;22(6):753-6. 5829323
111. EUCTR2004-004053-26-SE. An explorative use open-label, multi-center, randomized trial studying the safety and efficacy of levetiracetam (500 mg/day to 3000 mg/day) and valproate (600 mg/day to 3000 mg/day) as monotherapy in newly diagnosed patients over the age of 65 years - Scandinavian elderly study. www.clinicaltrialsregister.eu (accessed 23 August 2016). 5829325
112. EUCTR2010-018284-42-NL. A trial comparing efficacy, safety and tolerance between levetiracetam and valproic acid in children with epilepsy. www.clinicaltrialsregister.eu (accessed 11 September 2015). 5829327
113. Fakhoury TA, Hammer AE, Vuong A, Messenheimer JA. Efficacy and tolerability of conversion to monotherapy with lamotrigine compared with valproate and carbamazepine in patients with epilepsy. Epilepsy & Behavior 2004;5(4):532-8. 5829329
114. French JA, Temkin NR, Shneker BF, Hammer AE, Caldwell PT, Messenheimer JA. Lamotrigine XR conversion to monotherapy: first study using a historical control group. Neurotherapy 2012;9(1):176-84. 5829331
115. Gilliam F, Vazquez B, Sackellares JC, Chang GY, Messenheimer J, Nyberg J, et al. An active-control trial of lamotrigine monotherapy for partial seizures. Neurology 1998;51(4):1018-25. 5829333
116. Gruber CM, Brock JT, Dyken MD. Comparison of the effectiveness of phenobarbital, mephobarbital, primidone, dipheylhydantoin, ethotoin, metharbital, and methylphenylhydantion in motor seizures. Clinical Pharmacology & Therapeutics 1962;3:23-8. 5829335
117. Hakami T, O'Brien TJ, Petty SJ, Sakellarides M, Christie J, Kantor S, et al. Monotherapy with levetiracetam versus older AEDs: a randomized comparative trial of effects on bone health. Calcified Tissue International 2016;98(6):556-65. 5829337
118. Hakami T, Todaro M, Petrovski S, MacGregor L, Velakoulis D, Tan M, et al. Substitution monotherapy with levetiracetam vs older antiepileptic drugs: a randomized comparative trial. Archives of Neurology 2012;69(12):1563-71. 5829338
119. ISRCTN73223855. A randomised controlled trial of phenobarbitone and phenytoin for newly diagnosed epilepsy in adults. www.isrctn.com (accessed 11 September 2015). 5829340
120. Kaminow L, Schimschock JR, Hammer AE, Vuong A. Lamotrigine monotherapy compared with carbamazepine, phenytoin, or valproate monotherapy in patients with epilepsy. Epilepsy & Behavior 2003;4(6):659-66. 5829342
121. Kerr M, Kane K, Moorat A. Switching patients to monotherapy: efficacy and tolerability for Lamictal(r) compared to valproate. European Journal of Neurology 1999;6(Suppl 3):17. 5829344
122. Kerr M, Moorat A, Curtis P. Lamotrigine compared to valproate: a randomised open label switch to monotherapy study in patients with uncontrolled epilepsy. Journal of the Neurological Sciences 2001;187(Suppl 1):S291-2. 5829346
123. Loiseau P, Cohadon S, Jogeix M, Legroux M, Dartigues JF. Efficacy of sodium valproate in partial epilepsy. Crossed study of valproate and carbamazepine. Revue Neurologique 1984;140(6-7):434-7. 5829348
124. Reinikainen K, Keranen T, Hallikainen E, Riekkinen PJ. Substitution of diphenylhydantoin by oxcarbazepine or carbamazepine: double-blind study. Acta Neurologica Scandinavica 1984;69(Suppl 98):89-90. 5829350
125. Reinikainen KJ, Keranen T, Halonen T, Komulainen H, Riekkinen PJ. Comparison of oxcarbazepine and carbamazepine: a double-blind study. Epilepsy Research 1987;1(5):284-9. 5829352
126. Rosenow F, Schade-Brittinger C, Burchardi N, Bauer S, Klein KM, Weber Y, et al. LaLiMo Study Group. The LaLiMo Trial: lamotrigine compared with levetiracetam in the initial 26 weeks of monotherapy for focal and generalised epilepsy--an open-label, prospective, randomised controlled multicenter study. Journal of Neurology, Neurosurgery & Psychiatry 2012;83(11):1093-8. 5829354
127. Simonsen N, Olsen PZ, Kuhl V. Carbamazepine versus diphenylhydantoin in psychomotor epilepsy. A double blind study of antiepileptic effect and side effects. Ugeskrift for Laeger 1975;137(41):2392-6. 5829356
128. Simonsen N, Zander Olsen P, Kuhl V. A double blind study of carbamazepine and diphenylhydantoin in temporal lobe epilepsy. Acta Neurologica Scandinavica 1975;52(Suppl 60):39-42. 5829358
129. Taragano FE, Loñ L, Sarasola D, Serrano C. Is oxcarbazepine better than phenytoin for the treatment of dementia patients complicated with secondary epilepsy? A comparative study. Revista Neurologica Argentina 2003;28(4):209-16. 5829360
130. Chen YB, Hao YP, Hao XS, Liang D. Clinical efficacy of oxcarbazepine suspension in children with focal epilepsy. Zhongguo Dang Dai Er Ke Za Zhi 2013;15(5):340-2. 5829362
131. Chen YB, Wang JT, Wang LJ, Liang D. Clinical observation of oxcarbazepine suspension monotherapy for 2 to 4-year-old patients newly diagnosed as partial epilepsy. Chinese Journal of Neurology 2012;45(10):730-3. 5829363
132. IRCT201202068943N1. Efficacy of oxcarbazepine and phenytoin in control of epilepsy in the elderly. www.irct.ir/searchresult.php?id=8943&number=1 (accessed 23 August 2016). 5829365
133. Korean Zonisamide Study Group. Double-blind, randomized, comparative clinical trial of zonisamide and carbamazepine as initial monotherapy in newly diagnosed epilepsy. Journal of Korean Epilepsy Society 1999;3(1):50-7. 5829367
134. NCT00154076. A multicenter comparative trial of zonisamide and topiramate as initial monotherapy in untreated epilepsies. ClinicalTrials.gov (accessed 23 August 2016). 5829369
135. Park WS, Kim CW, Park SP, Kwon SH. Safety and efficacy of topiramate monotherapy in children with recent-onset seizures. Journal of Korean Epilepsy Society 2001;5(1):65-9. 5829371
136. Rysz A. Effect of monotherapy with phenytoin or carbamazepine on somatosensory evoked potentials in patients with newly diagnosed epilepsy. Polski Tygodnik Lekarski 1994;49(4-5):79-81. 5829373
137. Xu F, Sun HB. Comparative study for retention rate of new antiepileptic drugs as an initial monotherapy in complex partial epilepsy. Chinese Journal of New Drugs 2012;21(11):1265-8. 5829375
138. ACTRN12615000556549. EpiNet-First Trial 2: comparison of efficacy of levetiracetam and sodium valproate in people with previously untreated epilepsy who have generalised seizures. In: Auckland District Health B, editor. 2015 (accessed 23 August 2016). 5829377
139. ACTRN12615000639527. EpiNet-First Trial 3: comparison of efficacy of levetiracetam and lamotrigine in people with previously untreated epilepsy who have generalised seizures, and for whom sodium valproate is not deemed an acceptable anti-epileptic drug. In: Auckland District Health B, editor. 2015 (accessed 23 August 2016). 5829379
140. ACTRN12615000640505. EpiNet-First Trial 4: comparison of efficacy of levetiracetam, lamotrigine and sodium valproate in people with previously untreated epilepsy who have unclassified seizures. In: Auckland District Health B, editor. 2015 Vol. (accessed 23 August 2016). 5829381
141. ACTRN12615000641594. EpiNet-First Trial 5: comparison of efficacy of levetiracetam and lamotrigine in people with previously untreated epilepsy who have unclassified seizures, and for whom sodium valproate is not deemed an acceptable anti-epileptic drug. In: Auckland District Health B, editor. 2015 (accessed 23 Agust 2016). 5829383
142. ACTRN12615000643572. EpiNet-First Trial 1: comparison of efficacy of levetiracetam, lamotrigine and carbamazepine in people with previously untreated epilepsy who have focal seizures. In: Auckland District Health B, editor. 2015 (accessed 23 August 2016). 5829385
143. NCT01891890. Cognitive AED outcomes in pediatric localization related epilepsy (COPE). ClinicalTrials.gov (accessed 23 August 2016). 5829387
144. NCT02201251. A study to investigate the safety of the drugs topiramate and levetiracetam in treating children recently diagnosed with epilepsy. ClinicalTrials.gov (accessed 23 August 2016). 5829389
145. Altman DG, De Stavola BL, Love SB, Stepniewska KA. Review of survival analyses published in cancer journals. British Journal of Cancer 1995;72:511-8.
146. Annegers JF, Dubinsky S, Coan SP, Newmark ME, Roht L. The incidence of epilepsy and unprovoked seizures in multiethnic, urban health maintenance organizations. Epilepsia 1999;40(4):502-6.
147. Berg AT, Berkovic SF, Brodie MJ, Buchhalter J, Cross JH, van Emde Boas W, et al. Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005-2009. Epilepsia 2010;51:676-85.
148. Bourgeois B, Beaumanoir A, Blajev B, de la Cruz N, Despland PA, Egli M, et al. Monotherapy with valproate in primary generalized epilepsies. Epilepsia 1987;28(Suppl 2):S8-11.
149. Brodie MJ, Dichter MA. Antiepileptic drugs. New England Journal of Medicine 1996;334(3):168-75.
150. Bromley RL, Mawer GE, Briggs M, Cheyne C, Clayton-Smith J, García-Fiñana M, et al. The prevalence of neurodevelopmental disorders in children prenatally exposed to antiepileptic drugs. Journal of Neurology, Neurosurgery and Psychiatry 2013;84(6):637-43.
151. Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. Journal of Clinical Epidemiology 1997;50(6):683-91.
152. Canger R, Battino D, Canevini MP, Fumarola C, Guidolin L, Vignoli A, et al. Malformations in offspring of women with epilepsy: a prospective study. Epilepsia 1999;40(9):1231-6.
153. Carl GF, Smith ML. Phenytoin-folate interactions: differing effects of the sodium salt and the free acid of phenytoin. Epilepsia 1992;33(2):372-5.
154. Cockerell OC, Johnson AL, Sander JW, Hart YM, Shorvon SD. Remission of epilepsy: results from the National General Practice Study of Epilepsy. Lancet 1995;346(8968):140-4.
155. Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised clinical and electroencephalographic classification of epileptic seizures. Epilepsia 1981;22(4):489-501.
156. Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia 1989;30(4):389-99.
157. Coulter DA, Sombati S, DeLorenzo RJ. Selective effects of topiramate on sustained repetitive firing and spontaneous bursting in cultured hippocampal neurons. Epilepsia 1993;34(Suppl 2):123.
158. Delgado-Escueta AV, Enrile-Bacsal F. Juvenile myoclonic epilepsy of Janz. Neurology 1984;34(3):285-94.
159. Dias S, Welton NJ, Caldwell DM, Ades AE. Checking consistency in mixed treatment comparison meta-analysis. Statistics in Medicine 2010;29((7-8)):932-44.
160. Electronic Medicines Compendium (eMC). www.medicines.org.uk/emc/ (accessed 11 October 2016).
161. Endoh A, Kinno I, Kawai M, Hiramatsu M, Mori A. Effect of zonisamide on neurotransmitter in mouse brain. Neurosciences 1994;20(suppl):P173-6.
162. Engel J, Pedley TA, Aicardi J. Antiepileptic Drugs. Epilepsy: A Comprehensive Textbook. Vol. 3, Lippincott Williams & Wilkins, 2008:1488-9.
163. Epilepsy Foundation of America, Inc. Seizure and Epilepsy Medicines. www.epilepsy.com/learn/treating-seizures-and-epilepsy/seizure-and-epilepsy-medicines?gclid=COarmvHni7kCFXLJtAodYREA1w (accessed 20 August 2013).
164. Faigle JW, Menge GP. Metabolic characteristics of oxcarbazepine (Trileptal) and their beneficial implications for enzyme induction and drug interactions. Behaviour Neurology 1990;3(1):21-30.
165. U.S. Food and Drug Administration. www.fda.gov/ (accessed 11 October 2016).
166. French JA, Kanner AM, Bautista J, Abou-Khalil B, Browne T, Harden CL, et al. Efficacy and tolerability of the new antiepileptic drugs I: treatment of new onset epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 2004;62(8):1252-60.
167. French JA, Kanner AM, Bautista J, Abou-Khalil B, Browne T, Harden CL, et al. Appendix C: Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new onset epilepsy: Report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. CONTINUUM Lifelong Learning in Neurology 2007;13:203-11.
168. Gillard M, Chatelain P, Fuks B. Binding characteristics of levetiracetam to synaptic vesicle protein 2A (SV2A) in human brain and in CHO cells expressing the human recombinant protein. European Journal of Pharmacology 2006;536(1-2):102-8.
169. Gladstone DJ, Bologa M, Maguire C, Pastuszak A, Koren G. Course of pregnancy and fetal outcome following maternal exposure to carbamazepine and phenytoin: a prospective study. Reproductive Toxicology 1992;6(3):257-61.
170. Glauser T, Ben-Menachem E, Bourgeois B, Cnaan A, Chadwick D, Guerreiro C, et al. ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 2006;47(7):1094-120.
171. GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336:924.
172. Granger P, Biton B, Faure C, Vige X, Depoortere H, Graham D, et al. Modulation of the gamma-aminobutyric acid type A receptor by the antiepileptic drugs carbamazepine and phenytoin. Molecular Pharmacology 1995;47:1189-96.
173. Grant SM, Faulds D. Oxcarbazepine. A review of its pharmacology and therapeutic potential in epilepsy, trigeminal neuralgia and affective disorders. Drugs 1992;43:873-88.
174. Grünewald R, Panayiotopoulos CP. Juvenile myoclonic epilepsy: a review. Archives of Neurology 1993;50:594-8.
175. Hauser WA, Annegers JF, Kurland LT. Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota 1935 - 1984. Epilepsia 1993;34:453-68.
176. Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Statistics in Medicine 2002;21:1539-58.
177. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
178. Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
179. Higgins JPT, Jackson D, Barrett JK, Lu G, Ades, White IR. Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies. Research Synthesis Methods 2012;3:98-110.
180. Hill DR, Suman-Chauhan N, Woodruff GN. Localization of [3H] gabapentin to a novel site in rat brain: autoradiographic studies. European Journal of Pharmacology 1993;244:303-9.
181. Hirtz D, Thurman DJ, Gwinn-Hardy K, Mohamed M, Chaudhuri AR, Zalutsky R. How common are the "common" neurologic disorders?. Neurology 2007;68:326-37.
182. ILAE Commission on Antiepileptic Drugs. Considerations on designing clinical trials to evaluate the place of new antiepileptic drugs in the treatment of newly diagnosed and chronic patients with epilepsy. Epilepsia 1998;39(7):799-803.
183. Jackson D, White IR, Riley R. Quantifying the impact of between-study heterogeneity in multivariate meta-analyses. Statistics in Medicine 2012;31:3805-20.
184. Jeavons PM, Clark JE, Maheshwan MC. Treatment of generalized epilepsies of childhood and adolescence with sodium valproate. Developmental Medicine and Child Neurology 1977;19:9-25.
185. Joseph PD, Craig JC, Caldwell PH. Clinical trials in children. British Journal of Clinical Pharmacology 2015 Mar;79(3):357-69.
186. Juul-Jenson P, Foldspang A. Natural history of epileptic seizures. Epilepsia 1983;24:297-312.
187. Kawai M, Hiramatsu M, Endo A, Kinno I, Endo Y, Suh M, et al. Effect of zonisamide on release of aspartic acid and gamma-aminobutyric acid from the hippocampal slices of E1 mice. Neurosciences 1994;20:115-9.
188. Kirkham JJ, Dwan KM, Altman DG, Gamble C, Dodd S, Smyth R, et al. The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews. BMJ 2010;340:c365.
189. Kwan P, Brodie MJ. Early identification of refractory epilepsy. New England Journal of Medicine 2000;342:314-9.
190. Lees G, Leach MJ. Studies on the mechanism of action of the novel anti-convulsant lamotrigine (Lamictal) using primary neuroglial cultures from rat cortex. Brain Research 1993;612:190-99.
191. Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
192. Liporace JD, Sperling MR, Dichter MA. Absence seizures and carbamazepine in adults. Epilepsia 1994;35(5):1026-8.
193. Lu G, Ades A. Assessing evidence inconsistency in mixed treatment comparisons. Journal of the American Statistical Association 2006;101(474):447-59.
194. Lynch BA, Lambeng N, Nocka K, Kensel-Hammes P, Bajjalieh SM, Matagne A, et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. National Academy of Sciences of the United States of America. 2004; Vol. 101(26):9861-6.
195. MacDonald BK, Johnson AL, Goodridge DM, Cockerell OC, Sander JWA, Shorvon SD. Factors predicting prognosis of epilepsy after presentation with seizures. Annals of Neurology 2000;48:833-41.
196. Malafosse A, Genton P, Hirsch E, Marescaux C, Broglin D, Bernasconi R. Idiopathic Generalised Epilepsies: Clinical, Experimental and Genetic. Eastleigh: John Libbey and Company, 1994.
197. Marson AG, Williamson PR, Hutton JL, Clough HE, Chadwick DW. Carbamazepine versus valproate monotherapy for epilepsy. Cochrane Database of Systematic Reviews 2000, Issue 3. [DOI: 10.1002/14651858.CD001030]
198. McClean MJ. Gabapentin. Epilepsia 1995;36(Suppl 2):72-86.
199. McLean MJ, MacDonald RL. Sodium valproate, but not ethosuximide, produces use- and voltage-dependent limitation of high frequency repetitive firing of action potentials of mouse central neurons in cell culture. Journal of Pharmacology and Experimental Therapeutics 1986;237:1001-11.
200. McLean MJ. Gabapentin in the management of convulsive disorders. Epilepsia 1999;40(Suppl 6):S39-50; discussion S73-4.
201. Meador K, Reynolds M, Crean S, Fahrbach K, Probst C. Pregnancy outcomes in women with epilepsy: a systematic review and meta-analysis of published pregnancy registries and cohorts. Epilepsy Research 2008;81:1-13.
202. Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Medicine 2009;6(7):e1000097. [DOI: 10.1371/journal.pmed1000097]
203. Morrow J, Russel A, Guthrie E, Parsons L, Robertson I, Waddell R, et al. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. Journal of Neurology, Neurosurgery and Neuropsychiatry 2006;77(2):193-8.
204. Nevitt SJ, Sudell M, Tudur Smith C, Marson A. Topiramate versus carbamazepine monotherapy for epilepsy: an individual participant data review. Cochrane Database of Systematic Reviews 2016, Issue 12. [DOI: 10.1002/14651858.CD012065.pub2]
205. Ngugi AK, Bottomley C, Kleinschmidt I, Sander JW, Newton CR. Estimation of the burden of active and life-time epilepsy: a meta-analytic approach. Epilepsia 2010;51:883-90.
206. National Institute for Health and Care Excellence. The epilepsies: the diagnosis and management of the epilepsies in adults and children and primary and secondary care. NICE guidelines [CG137] Published date: January 2012. Available from www.nice.org.uk/guidance/cg137.
207. National Institute of Neurological Disorders and Stroke (NINDS). The epilepsies and seizures: hope through research. www.ninds.nih.gov/disorders/epilepsy/curing_the_epilepsies_brochure.pdf (accessed 11 October 2016).
208. Nolan SJ, Sutton L, Marson A, Tudur Smith C. Consistency of outcome and statistical reporting of time-to-event data: the impact on Cochrane Reviews and meta-analyses in epilepsy. 21st Cochrane Colloquium: Better Knowledge for Better Health. Quebec City, 2013:114-5.
209. Nolan SJ, Tudur Smith C, Pulman J, Marson AG. Phenobarbitone versus phenytoin monotherapy for partial onset seizures and generalised onset tonic-clonic seizures. Cochrane Database of Systematic Reviews 2013, Issue 1. [DOI: 10.1002/14651858.CD002217.pub2]
210. Nolan SJ, Muller M, Tudur Smith C, Marson AG. Oxcarbazepine versus phenytoin monotherapy for epilepsy. Cochrane Database of Systematic Reviews 2013, Issue 5. [DOI: 10.1002/14651858.CD003615.pub3]
211. Nolan SJ, Marson AG, Weston J, Tudur Smith C. Carbamazepine versus phenytoin monotherapy for epilepsy: an individual participant data review. Cochrane Database of Systematic Reviews 2015, Issue 8. [DOI: 10.1002/14651858.CD001911.pub2]
212. Nolan SJ, Tudur Smith C, Weston J, Marson AG. Lamotrigine versus carbamazepine monotherapy for epilepsy: an individual participant data review. Cochrane Database of Systematic Reviews 2016, Issue 11. [DOI: 10.1002/14651858.CD001031.pub3]
213. Nolan SJ, Marson AG, Weston J, Tudur Smith C. Carbamazepine versus phenobarbitone monotherapy for epilepsy: an individual participant data review. Cochrane Database of Systematic Reviews 2016, Issue 12. [DOI: 10.1002/14651858.CD001904.pub3]
214. Nolan SJ, Marson AG, Pulman J, Tudur-Smith C. Phenytoin versus valproate monotherapy for partial onset seizures and generalised onset tonic-clonic seizures: an individual participant data review. Cochrane Database of Systematic Reviews 2016, Issue 4. [DOI: 10.1002/14651858.CD001769.pub3]
215. Nulman I, Scolnik D, Chitayat D, Farkas LD, Koren G. Findings in children exposed in utero to phenytoin and carbamazepine monotherapy: independent effects of epilepsy and medications. American Journal of Medical Genetics 1997;68(1):18-24.
216. Okada M, Kawata Y, Mizuno K, Wada K, Kondo T, Kaneko S. Interaction between Ca2+, K+, carbamazepine and zonisamide on hippocampal extracellular glutamate monitored with a microdialysis electrode. British Journal of Pharmacology 1998;124:1277-85.
217. Olafsson E, Ludvigsson P, Gudmundsson G, Hesdorfer D, Kjartansson O, Hauser WA. Incidence of unprovoked seizures and epilepsy in Iceland and assessment of the epilepsy syndrome classification: a prospective study. Lancet Neurology 2005;4:627-34.
218. Ornoy A. Valproic acid in pregnancy: how much are we endangering the embryo and fetus?. Reproductive Toxicology 2009;28(1):1-10.
219. Palmer TM, Sterne JAC. Meta-Analysis in Stata: An Updated Collection from the Stata Journal, Second Edition. Stata Press, 2016.
220. Parmar MKB, Torri V, Stewart L. Extracting summary statistics to perform meta-analysis of the published literature for survival endpoints. Statistics in Medicine 1998;17:2815-34.
221. Penry JK, Dean JC, Riela AR. Juvenile myoclonic epilepsy: long term response to therapy. Epilepsia 1989;30:19-23.
222. Pinder RM, Brogden RN, Speight TM, Avery GS. Sodium valproate: a review of its pharmacological properties and therapeutic efficacy in epilepsy. Drugs 1977;13:81-123.
223. Ragsdale DS, Scheuer T, Catterall WA. Frequency and voltage-dependent inhibition of type IIA Na+ channels, expressed in a mammalian cell line, by local anesthetic, antiarrhythmic, and anticonvulsant drugs. Molecular Pharmacology 1991;40(5):756-65.
224. Rho JM, Donevan, SD, Rogawski MA. Direct activation of GABAA receptors by barbiturates in cultured rat hippocampal neurons. Journal of Physiology 1996;497(2):509-22.
225. Sackellares JC, Ramsay RE, Wilder BJ, Browne TR 3rd, Shellenberger MK. Randomized, controlled clinical trial of zonisamide as adjunctive treatment for refractory partial seizures. Epilepsia 2004;45(6):610-7.
226. Salanti G, Del Giovane C, Chaimani A, Caldwell DM, Higgins JP. Evaluating the quality of evidence from a network meta-analysis. PloS one 2014 Jul 3;9(7):e99682.
227. Sander JW, Shorvon SD. Epidemiology of the epilepsies. Journal of Neurology, Neurosurgery, and Psychiatry 1996;61(5):433-43.
228. Sander JW. The use of anti-epileptic drugs - principles and practice. Epilepsia 2004;45(6):28-34.
229. SAS Institute Inc. Base SAS. Version 9.3. Cary, NC, USA: SAS Institute Inc, 2011.
230. Schauf CL. Zonisamide enhances slow sodium inactivation in Myxicola. Brain Research 1987;413:185-8.
231. Scheinfeld N. Phenytoin in cutaneous medicine: its uses, mechanisms and side effects. Dermatology Online Journal 2003;9(3):6.
232. Shakir RA. Sodium valproate, phenytoin and carbamazepine as sole anticonvulsants. The place of sodium valproate in the treatment of epilepsy. London: Academic Press Inc (London) Ltd and the Royal Society of Medicine, 1980:7-16.
233. Shields WD, Saslow E. Myoclonic, atonic, and absence seizures following institution of carbamazepine therapy in children. Neurology 1983;33:1487-9.
234. Snead OC, Hosey LC. Exacerbation of seizures in children by carbamazepine. New England Journal of Medicine 1985;313(15):916-21.
235. StataCorp LP. Stata Statistical Software: Release 14. College Station, TX: StataCorp LP, 2015.
236. Suzuki S, Kawakami K, Nishimura S, Watanabe Y, Yagi K, Seino M, et al. Zonisamide blocks T-type calcium channel in cultured neurons of rat cerebral cortex. Epilepsy Research 1992;12:21-7.
237. Tomson T, Battino D, Bonizzoni E, Craig J, Lindhout D, Sabers A, et al. Dose-dependent risk of malformation with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurology 2011;10(7):609-17.
238. Trimble MR, Cull C. Children of school age: the influence of antiepileptic drugs on behavior and intellect. Epilepsia 1988;29(Suppl 3):S15-19.
239. Tudur Smith C, Marson AG, Chadwick DW, Williamson PR. Multiple treatment comparisons in epilepsy monotherapy trials. Trials 2007;5(8):34.
240. Wallace H, Shorvon SD, Hopkins A, O'Donoghue M. National Society of Epilepsy Guidelines. London: Royal College of Physicians, 1997.
241. Weston J, Bromley R, Jackson CF, Adab N, Clayton-Smith J, Greenhalgh J, et al. Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child. Cochrane Database of Systematic Reviews 2016, Issue 11. [DOI: 10.1002/14651858.CD010224.pub2]
242. White HS, Brown SD, Woodhead JH, Skeen GA, Wolf HH. Topiramate enhances GABA-mediated chloride flux and GABA-evoked chloride currents in murine brain neurons and increases seizure threshold. Epilepsy Research 1997;28:167-79.
243. White IR. Multivariate random-effects meta-analysis. Stata Journal 2009; Vol. 9, issue 1:40-56.
244. White IR. Network meta-analysis. Stata Journal 2015;15(4):951-85.
245. World Health Organization. Global comparative assessments in the health sector: disease burden, expenditures and intervention packages. Collected reprints from the Bulletin of the World Health Organization. 1994. Available from apps.who.int/iris/handle/10665/41177 (accessed 13 June 2017).
246. Wilder BJ. Phenytoin: clinical use. Antiepileptic drugs. New York: Raven Press, 1995:339-44.
247. Williamson PR, Tudur Smith C, Hutton JL, Marson AG. Aggregate data meta-analysis with time-to-event outcomes. Statistics in Medicine 2002;21(11):3337-51.
248. Willow M, Gonoi T, Catterall WA. Voltage clamp analysis of the inhibitory actions of diphenyihydantoin and carbamazepine on voltage sensitive sodium channels in neuroblastoma cells. Molecular Pharamcology 1985;27:549-58.
249. Wyllie E, Gupta A, Lachhwani DK. Antiepileptic Medications. The Treatment of Epilepsy: Principles & Practice. 4th Edition. Lippincott Williams & Wilkins, 2006:650.
250. Zhu W, Rogawski A. Zonisamide depresses excitatory synaptic transmission by a presynaptic action. Epilepsia 1999;40(suppl 7):245.
251. Nolan SJ, Sudell M, Weston J, Tudur Smith C, Marson AG. Antiepileptic drug monotherapy for epilepsy: a network meta-analysis. Cochrane Database of Systematic Reviews 2014, Issue 12. [DOI: 10.1002/14651858.CD011412]